MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze OCS →
    • FindStock Picks / Stock Screener
    • Value · OCSIntrinsic Value Calculator
    • Invest · OCSInvestment Case
    • Hold · OCS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OCS

OCS

Oculis Holding AG

$7.29
-0.11
 (-1.49%)
Exchange:  NASDAQ
Market Cap:  448.977M
Shares Outstanding:  32.733M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Riad Sherif
Full Time Employees:  60
Address: 
Bahnhofstrasse 7
Zug
ZG
6300
CH
Website:  https://oculis.com
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
OCOCS logoOCSOculis Holding AG449.0M——-38.9%
ARARVN logoARVNArvinas, Inc.449.7M40.2—-2.2%
PRPROK logoPROKProKidney Corp.447.2M——-68.1%
ALALLO logoALLOAllogene Therapeutics, Inc.452.6M——-34.8%
RGRGNX logoRGNXREGENXBIO Inc.457.1M——-52.7%
CBCBIO logoCBIOCrescent Biopharma, Inc.439.8M——-102.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue06860
Gross Profit0-51,3970
EBITDA-87,093-85,531-93,344.269
Operating Income-80,714-73,204-79,145.361
Net Income-88,802-85,777-94,508.181

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets114,353120,353236,231.054
Total Liabilities20,62546,97039,938.317
Total Stockholders Equity93,72873,383196,292.736
Total Debt6051,1802,315.626
Cash and Cash Equivalents38,32727,70881,421.389

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-53,845-47,499-62,221.045
Capital Expenditure-48-230-287.470
Free Cash Flow-53,893-47,729-62,508.516
Net Income-88,695-85,937-94,508.181
Net Change in Cash18,541-10,61957,171.348

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)158,598.790Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)617,422.643Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)335,914.643Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)20,451.833Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)96,254.951Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)49,746.466Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)10,582.599Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)70,467.062Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)33,725.359Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,135,206.674Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)4,419,342.072Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,404,384.956Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.640Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.200Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
1628.99
?Net Income
 (TTM)
: 
-98.817M  ?P/E
 (TTM)
: 
-4.95
?Enterprise Value
 (TTM)
: 
398.379M  ?EV/FCF
 (TTM)
: 
-6.03
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-42.93%  ?ROIC
 (TTM)
: 
-38.94%
?Net Debt
 (TTM)
: 
-123.561M  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
1.93  ?Current Ratio
 (TTM)
: 
8.35

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates OCS intrinsic value between $8.98 – $13.56 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate OCS Intrinsic Value

Common questions about OCS valuation

Is Oculis Holding AG (OCS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Oculis Holding AG (OCS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OCS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OCS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OCS’s P/E ratio?

You can see OCS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OCS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OCS a good long-term investment?

Whether OCS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Oculis Holding AG

  • Oculis Holding AG intrinsic value calculatorEstimate what the business is worth
  • Oculis Holding AG 5-year outlookWhat has to go right, and what could go wrong
OCS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.49
MarketSnap

Trading Metrics:

Open: 7.26   Previous Close: 7.4
Day Low: 7.16   Day High: 7.4
Year Low: 7.11   Year High: 34.48
Price Avg 50: 10.87   Price Avg 200: 19.57
Volume: 293677   Average Volume: 340289

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Oculis Announces Resignation of Lionel Carnot from Board of Directors
30-09-2026 16:46
Oculis Announces Resignation of Lionel Carnot from Board of Directors
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026
21-09-2026 06:00
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
29-05-2026 16:05
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
24-08-2026 04:00
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
03-08-2026 04:00
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02-07-2026 04:00
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze OCS →
    • FindStock Picks / Stock Screener
    • Value · OCSIntrinsic Value Calculator
    • Invest · OCSInvestment Case
    • Hold · OCS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read